References
- 2018. Alzheimer’s disease facts and figures. [cited 2018 Jun 11] Available from: https://www.alz.org/facts/overview.asp
- Li R, Lindholm K, Yan L-B, et al. Amyloid β peptide load is correlated with increased β-secretase activity in sporadic Alzheimer’s disease patients. Proc Natl Acad Sci USA. 2004;101:3632–3637.
- Scott JD, Li SW, Brunskil AP, et al. Discovery of the 3-imino-1,2,4-thiadiazine 1,1-dioxide derivative verubecestat (MK-8931)- a β-site amyloid precursor protein cleaving enzyme 1 inhibitor for the treatment of Alzheimer’s disease. J Med Chem. 2016;59:10435–10450.
- Egan MF, Kost J, Voss T, et al. Randomized trial of verubecestat for prodromal Alzheimer’s disease. N Eng J Med. 2019;380:1408–1420.
- Egan MF, Kost J, Tariot PN, et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2018;378:1691–1703.
- Merck Sharp & Dohme Corp. Efficacy and safety trial of verubecestat (MK-8931) in participants with prodromal Alzheimer’s disease (MK-8931-019) (APECS). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000. [cited 2002 Feb 27] Available from: https://clinicaltrials.gov/ct2/show/NCT01953601. NLM Identifier: NCT01953601.
- Kennedy ME, Stamford AW, Chen X, et al. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients. Sci Transl Med. 2016;8:363ra150.
- Merck Sharp & Dohme Corp. An open-label study investigating MK-8931 in participants with mild and moderate hepatic insufficiency (MK-8931-016). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2002 Feb 27]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02910739. NLM Identifier: NCT02910739.
- Merck Sharp & Dohme Corp. A study of the safety, tolerability, and pharmacodynamics of MK-8931 in participants with Alzheimer’s disease (MK-8931-010 AM1 [P07820 AM1]). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2002 Feb 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT01496170. NLM Identifier: NCT01496170.
- Merck Sharp & Dohme Corp. A two-part, single-dose study of the pharmacokinetics of MK-8931 in subjects with renal insufficiency (MK-8931-009 [P08535]). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2002 Feb 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT01537757. NLM Identifier: NCT01537757.
- Merck Sharp & Dohme Corp. An efficacy and safety trial of Verubecestat (MK-8931) in mild to moderate Alzheimer’s disease (P07738) (EPOCH). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2002 Feb 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT01739348. NLM Identifier: NCT01739348.
- AstraZeneca. Update on phase III clinical trials of lanabecestat for Alzheimer’s disease. [cited 2019 Jun 13] Available from: https://www.astrazeneca.com/media-centre/press-releases/2018/update-on-phase-iii-clinical-trials-of-lanabecestat-for-alzheimers-disease-12062018.html
- Henley D, Raghavan N, Sperling R, et al. Preliminary results of a trial of atabecestat in preclinical Alzheimer’s disease. N Engl J Med. 2019;380:1483–1485.
- Eli Lilly and Company. AstraZeneca. An efficacy and safety study of Lanabecestat (LY3314814) in early Alzheimer’s Disease (AMARANTH). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2002 Feb 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT02245737. NLM Identifier: NCT02245737.
- Alzforum Cognitive decline trips up API trials of BACE inhibitors. [cited 2019 Aug 5]. Available from: https://www.alzforum.org/news/research-news/cognitive-decline-trips-api-trials-bace-inhibitor
- Janssen Research & Development, LLC. An efficacy and safety study of atabecestat in participants who are asymptomatic at risk for developing Alzheimer’s Dementia (EARLY). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2002 Feb 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT02569398. NLM Identifier: NCT02569398.
- Novartis Pharmaceuticals. A study of CNP520 versus placebo in participants at risk for the onset of clinical symptoms of Alzheimer’s disease (Generation S2). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2002 Feb 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT03131453. NLM Identifier: NCT03131453.
- Novartis Pharmaceuticals. A study of CAD106 and CNP520 versus placebo in participants at risk for the onset of clinical symptoms of Alzheimer’s disease (Generation S1). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2002 Feb 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT02565511. NLM Identifier: NCT02565511.
- Eisai. Data safety monitoring board recommends continuation of phase III clinical studies of BACE inhibitor elenbecestat in early Alzheimer’s disease. [cited 2019 Jun 13] Available from: http://eisai.mediaroom.com/2019-03-29-Data-Safety-Monitoring-Board-Recommends-Continuation-Of-Phase-III-Clinical-Studies-Of-BACE-Inhibitor-Elenbecestat-In-Early-Alzheimers-Disease
- Eisai Co., Ltd. Biogen. A 24-month study to evaluate the efficacy and safety of elenbecestat (E2609) in subjects with early Alzheimer’s disease (MissionAD1). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2002 Feb 27]. Available from: https://clinicaltrials.gov/ct2/show/NCT02956486. NLM Identifier: NCT02956486.
- Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256:184–185.
- Panza F, Lozupone M, Solfrizzi V, et al. BACE inhibitors in clinical development for the treatment of Alzheimer;s disease. Expert Rev Neurother. 2018;11:847–857.
- Panza F, Lozupone M, Logroscrino G, et al. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2019;15:73–88.
- Herrup K. The case for rejecting the amyloid cascade hypothesis. Nat Neurosci. 2015;6:794–799.
- Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503–1527.